Global Information
회사소개 | 문의 | 비교리스트

진행성 재발형 다발성 경화증(PRMS) : 파이프라인 리뷰

Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 410973
페이지 정보 영문 35 Pages
가격
US $ 2,000 ₩ 2,408,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,816,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,224,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


진행성 재발형 다발성 경화증(PRMS) : 파이프라인 리뷰 Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 35 Pages

진행성 재발형 다발성 경화증(PRMS)이란 원발성 진행형 다발성 경화증(PPMS)이 재발한 패턴을 가리킵니다. 증상은 근육 마비 및 쇠약, 현기증, 만성적 통증 및 시력 변화 등입니다. 위험인자는 연령, 가족병력, 자가면역질환, 흡연 등입니다. 치료에는 면역 억제제를 사용합니다.

진행성 재발형 다발성 경화증(PRMS: Progressive Relapsing Multiple Sclerosis)의 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보 등을 최신 뉴스와 발표와 함께 전해드립니다.

서론

  • 조사 범위

진행성 재발형 다발성 경화증(PRMS) 개요

치료제 개발

  • 파이프라인 제품 : 개요

기업에서 개발중인 치료제

파이프라인 제품 상황 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 개발 참여 기업

  • Cognosci Inc
  • Genzyme Corp
  • MedImmune LLC
  • VivaCell Biotechnology Espana SL

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • COG-112
  • COG-133
  • GZ-402668
  • inebilizumab
  • VCE-0032

휴지 상태인 프로젝트

개발이 중지된 제품

부록

LSH 17.01.23

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Relapsing Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline landscape.

Progressive-relapsing multiple sclerosis (PRMS) refers to a pattern of relapses within primary-progressive MS (PPMS). Signs of PRMS include muscle spasms, weak muscles, dizziness, chronic pain and vision changes. Risk factors include age, family history, autoimmune diseases and smoking. Treatment includes immunosuppressant drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Relapsing Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Relapsing Multiple Sclerosis (PRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively.

Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Relapsing Multiple Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Relapsing Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Relapsing Multiple Sclerosis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Relapsing Multiple Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Relapsing Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Progressive Relapsing Multiple Sclerosis (PRMS) Overview
  • Therapeutics Development
    • Pipeline Products for Progressive Relapsing Multiple Sclerosis (PRMS) - Overview
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics under Development by Companies
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Products under Development by Companies
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Companies Involved in Therapeutics Development
    • Cognosci Inc
    • Genzyme Corp
    • MedImmune LLC
    • VivaCell Biotechnology Espana SL
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • COG-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COG-133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-402668 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCE-0032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Cognosci Inc, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by Genzyme Corp, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by MedImmune LLC, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Pipeline by VivaCell Biotechnology Espana SL, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Dormant Projects, H2 2016
  • Progressive Relapsing Multiple Sclerosis (PRMS) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Progressive Relapsing Multiple Sclerosis (PRMS), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q